Latest News and Press Releases

PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027...

Q1 updates: Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025Built out launch infrastructure and aligned field-based teams for upcoming launchesSettlement of senior convertible notes of $36.3M ...

Austin, TX, USA, May 06, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “RNA Targeting Small Molecule Drug Discovery Market Size, Trends and Insights By...

CARBOGEN AMCIS Shanghai Site achieves successful outcome in Unannounced NMPA GMP Inspection

SAN FRANCISCO, May 06, 2026 (GLOBE NEWSWIRE) -- Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that Scott McIvor, Chief Development...

- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 2026 - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only...

Fristads aiuta i clienti a ridurre l’impatto climatico – risparmi di CO₂e equivalenti a 1.850 voli di andata e ritorno tra Helsinki e Monaco nel 2025.

Fristads helpt klanten hun klimaatimpact te verminderen – CO₂e-besparingen gelijk aan 1.850 retourvluchten tussen Helsinki en München in 2025.

Fristads hjælper kunder med at reducere klimapåvirkningen – CO₂e-besparelser svarende til 1.850 returflyvninger mellem Helsinki og München i 2025.

Fristads hjälper kunder att minska klimatpåverkan – CO₂e-besparingar motsvarande 1 850 tur- och returflygningar mellan Helsingfors och München under 2025.